TL;DR: Medical device manufacturers are being pushed to treat SBOMs as a design-time security and compliance control, not a documentation afterthought, because about 96% of device software now depends on open source components and FDA requirements are tightening, according to Kusari. That shift makes software transparency, vulnerability correlation, and lifecycle accountability central to patient safety and regulatory readiness.
At a glance
What this is: This is an analysis of why SBOMs are moving from compliance paperwork to a design-time control for medical devices, with the central finding that component transparency now underpins safety, vulnerability response, and regulatory readiness.
Why it matters: It matters because medtech security teams need software supply-chain visibility early enough to govern vulnerabilities, end-of-life components, and disclosure obligations before patient impact and approval delays occur.
Context
Medical device cybersecurity now sits inside the design and regulatory lifecycle, not only the post-market response cycle. When software is embedded in implants, imaging systems, and monitoring devices, the security question becomes what components are present, how they are supported, and whether the organisation can prove that risk has been assessed before release.
The governance gap is that static inventories do not tell teams whether a component is exploitable, unsupported, or likely to affect patient safety. In medtech, SBOMs become a bridge between software transparency and action, and that bridge matters to quality, regulatory, and security teams as much as it does to engineering.
Key questions
Q: How should medical device teams make SBOMs operational instead of treating them as paperwork?
A: SBOMs become operational when they are generated automatically, machine-readable, and continuously matched to vulnerability and exploitability data. Teams should connect component inventory to ownership, support status, and remediation workflows so the result drives release decisions, regulatory evidence, and incident response rather than sitting in a document repository.
Q: Why do SBOMs matter so much for regulated medical devices?
A: They provide the evidence base for understanding what software is inside a device, which components are unsupported, and where known vulnerabilities may affect patient safety or product availability. In regulated environments, that traceability is essential because it links technical risk to quality, compliance, and customer communication obligations.
Q: What breaks when SBOMs are treated as static compliance documents?
A: When SBOMs are static, teams lose the operational value they were meant to provide. Vulnerability response slows, provenance becomes harder to prove, and missing or redacted components can hide real risk. Static SBOMs also fail to reflect release changes, so security and compliance teams end up working from stale dependency data.
Q: Who should own SBOM-based remediation decisions in a medical device programme?
A: Ownership should sit across engineering, security, quality, regulatory, and legal functions because SBOM findings affect product safety, release decisions, disclosure obligations, and post-market support. A single team can assemble the data, but no single team can govern the risk alone.
Technical breakdown
Why SBOMs need to be machine-readable in medtech
An SBOM only becomes operational when tools can parse it, correlate it, and compare it against vulnerability and support data. In medical devices, that means component name, version, origin, support status, and end-of-life data must be structured well enough for automated review. A PDF inventory is documentation; a machine-readable SBOM is an input to governance, remediation, and disclosure workflows. The technical value is not visibility alone but the ability to join component data with CVEs, exploitability signals, and device context.
Practical implication: Practitioners should build SBOM generation into the build pipeline and require machine-readable output that downstream tooling can consume.
How SBOMs connect component inventory to patient risk
An SBOM lists what is inside the device, but it does not by itself explain whether the component matters operationally. That is why the article emphasises pairing SBOMs with vulnerability intelligence and, where available, VEX data. CVE matching shows possible exposure, while additional context helps determine whether a specific flaw is actually reachable or safety-relevant in that device. For medtech, this distinction is critical because exploitability and clinical impact are not the same thing.
Practical implication: Teams should correlate SBOMs with vulnerability and exploitability data before deciding whether a finding changes patient-facing risk.
Why software anomalies belong in the same control model as SBOMs
The article points to FDA guidance that recommends documenting software anomalies and evaluating their safety impact, exploitability, and mitigations. That matters because the control problem is broader than inventory. A component may be present, supported, and patched, yet still create risk through a known anomaly or unsafe interaction. In practice, this creates a governance loop that spans design-time analysis, risk review, and post-market communication rather than a one-time submission artifact.
Practical implication: Practitioners should manage SBOMs, anomalies, and mitigations in a single review process instead of treating them as separate records.
Threat narrative
Attacker objective: The objective is to disrupt medical device availability or integrity in ways that create operational, regulatory, and patient-safety consequences.
- Entry occurs through the software supply chain when a device depends on open source or third-party components that may later prove vulnerable or unsupported.
- Credential or code-path abuse follows when those components are exploitable in the device build or runtime environment, creating a path to malfunction or disruption.
- Impact shows up as delayed treatment, interrupted hospital operations, recall pressure, or patient safety risk when the weakness reaches a live device fleet.
Breaches seen in the wild
- LiteLLM PyPI package breach: LiteLLM PyPI supply chain attack, credentials stolen from users.
- PyPI secrets exposure 2023: Researchers found 3,938 unique secrets in published PyPI packages, 768 still valid; a new release or yank does not remove them.
Read and download The State of NHI & AI Agent Breach Report 2026, covering 200+ breaches impacting Non-Human Identities including AI Agents.
NHI Mgmt Group analysis
SBOM governance is now a design-time security control, not a documentation exercise. In medtech, the SBOM has become the point where software composition, support status, and regulatory duty converge. That shifts the control from after-the-fact reporting to pre-release decision-making, which is exactly where safety risk should be governed.
Software transparency creates a lifecycle accountability problem that many device programmes have not fully operationalised. An SBOM exposes unsupported components, vulnerable dependencies, and vendor-origin ambiguity, but those findings only matter if ownership and remediation are assigned before release. The governance failure is not lack of data, it is lack of a decision process attached to that data.
Patient safety makes medtech supply-chain risk materially different from ordinary software risk. In many sectors, a vulnerable dependency mainly changes exposure. In medical devices, the same dependency can affect treatment timing, device function, and regulatory approval, so security teams have to treat SBOM review as part of quality assurance and change control.
Design-time transparency only works when it is paired with continuous exposure correlation. Open source prevalence in medical devices means component risk will keep changing after release, so static filing cannot carry the full governance load. Practitioners need a model that connects SBOMs to vulnerability intelligence, anomaly tracking, and partner disclosure so the control remains useful after shipment.
Software supply-chain accountability is now a core medtech procurement signal. Hospitals and buyers increasingly want proof that vendors can explain what is inside a device and how they will manage component risk over time. That makes SBOM maturity a commercial as well as a security requirement, and the organisations that can operationalise it will be better positioned for audits, recalls, and trust conversations.
What this signals
Design-time transparency only works when the organisation can act on it. Medtech teams should expect SBOMs to behave like a governance input, not a compliance attachment, because unsupported or vulnerable components become material when they are tied to device function and patient outcomes.
SBOM maturity is becoming a supply-chain readiness signal. The practical test is whether a programme can connect component data, anomaly review, and disclosure workflows quickly enough to support release decisions and post-market response.
For practitioners
- Build SBOM generation into the release pipeline Generate machine-readable SBOMs automatically as part of software build and release rather than assembling them manually after the fact.
- Correlate SBOMs with vulnerability and exploitability data Join SBOM records to CVE intelligence, support status, and exploitability context so teams can distinguish exposure from actionable patient risk.
- Track component support and end-of-life dates Maintain a live view of which components are supported, approaching end of life, or already unsupported, and tie that view to release approvals.
- Define cross-functional ownership for remediation decisions Assign engineering, security, regulatory, quality, and legal responsibility for reviewing anomalies, approving mitigations, and communicating device risk.
- Prepare a disclosure workflow for hospitals and regulators Create a safe process for sharing device risk information, remediation status, and mitigation guidance when a vulnerability affects deployed equipment.
Key takeaways
- SBOMs in medical devices now function as a design-time control because software composition, support status, and vulnerability exposure all affect safety and release decisions.
- The key governance gap is not whether teams can list components, but whether they can connect those components to exploitable risk, remediation ownership, and communication duties.
- Medtech programmes that automate SBOM creation and correlation will be better placed to handle audits, recalls, and patient-safety obligations without treating security as a post-release afterthought.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP API Security Top 10 and MITRE ATT&CK address the attack and risk surface, while NIST CSF 2.0, CIS Controls v8 and SLSA set the governance and control requirements practitioners need to meet.
| Framework | Control / Reference | Relevance |
|---|---|---|
| OWASP API Security Top 10 | API9 — Improper Inventory Management | SBOMs address the inventory visibility problem that underpins component risk in device software. |
| Recommendation — Treat component inventories as living records and map them to release, vulnerability, and support data. | ||
| NIST CSF 2.0 | PR.DS-10 — Integrity | The article ties software transparency to preserving trusted device behaviour and safe updates. |
| Recommendation — Use integrity controls to verify device software composition before release and after updates. | ||
| CIS Controls v8 | CIS-16 — Application Software Security | The article focuses on securing software composition and release processes for device code. |
| Recommendation — Apply application software security practices to govern dependencies and release-time risk review. | ||
| MITRE ATT&CK | TA0001;TA0040 — Initial Access; Impact | The incidents cited show how supply-chain compromise leads to operational disruption and patient impact. |
| Recommendation — Map dependency exposure to Initial Access and Impact pathways in threat detection and response plans. | ||
| SLSA | SLSA — Supply Chain Levels for Software Artifacts | The article is fundamentally about build provenance and software supply-chain assurance. |
| Recommendation — Adopt supply-chain provenance controls so device releases can be traced to verified build inputs. | ||
Key terms
- Software Bill of Materials: A software bill of materials is an inventory of the components and dependencies used in an application. It helps teams identify what they shipped, but it becomes most useful when paired with source verification, signature checks, and policy enforcement for third-party code.
- Software Anomaly: A software anomaly is a documented defect, irregularity, or condition that may affect how a device behaves, especially under attack or failure conditions. In medtech, anomalies matter because they must be assessed not only for technical severity, but also for safety impact, exploitability, and mitigation status.
- Software Supply Chain: A software supply chain is the set of tools, identities, dependencies, and processes that turn source code into deployed software. Because it relies on automation and privileged machine identities, it becomes a governance problem when access, signing, and deployment controls are too broad.
- Vulnerability Correlation: Vulnerability correlation is the process of linking related findings from different tools into a single, clearer view of risk. It helps teams avoid duplicate tickets and conflicting priorities. In mature programmes, correlation supports more accurate reporting, better ownership assignment, and faster remediation across AppSec and DevSecOps workflows.
Deepen your knowledge
NHI Mgmt Group covers identity security, NHI governance, and agentic AI through independent research, practitioner guides, and the NHI Foundation Level course. Explore nhimg.org for resources that connect identity governance to the broader security disciplines your programme depends on.
Published by the NHIMG editorial team on August 19, 2026.
Updated on October 12, 2026.
NHI Mgmt Group, the independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org